The FDA has approved Boehringer Ingelheim Pharmaceuticals’ Cyltezo (adalimumab-adbm) for the treatment of multiple chronic inflammatory diseases.

Cyltezo is the first biosimilar – that is, a biologic medical product that is almost an identical copy of an original product manufactured by a different company, in this case AbbVie’s Humira – from Boehringer Ingelheim to be approved by the FDA.